Despite Speaker Pelosi’s partisan approach to prescription drug pricing legislation, the building blocks for bipartisan consensus on a redesign of Medicare Part D’s outpatient drug benefit are being laid for a possible deal in Q1 of 2020.
Outsourced Pharma Chief Editor Louis Garguilo talks with two biotech CEOs about why they believe this industry should expect an infusion of technology and improved productivity in the coming years.
Here are the critical action items cell and gene therapy professionals should heed to keep pace with the sector’s ever-evolving regulations.
Though the U.S. hasn’t witnessed a biosimilar market explosion as many anticipated, uptake has slowly but surely been creeping upward. I’m far from alone in believing it’s too early to propose dismantling the biosimilar industry.
Virtual trials have been around for years, so why are they still met with skepticism? Clinical trial executives from Janssen and Astellas weigh in on this hot topic for 2020.
Six biopharma CEOs talk tariff wars, politics, and other concerns for 2020 and beyond.
Five biopharmaceutical industry finance experts share their perspectives for what the industry can expect in 2020 and beyond.
Seven biopharmaceutical executives share their perspectives on what to expect in biopharma manufacturing in 2020 and beyond.